Specialty preclinical CRO services

Explicyte Immuno-Oncology

We test novel drugs in validated in vitro and in vivo tumor models of cancer immunotherapies and analyze the anti-tumor immune response.

In vitro screening
In vitro screening
Phenotypic screening & in vitro profiling in cancer cells co-cultured with PBMCs
Read more
In vivo studies
In vivo studies
in vivo proof-of-concept studies in validated syngeneic mouse tumor models
Read more
Biomarker analysis
Biomarker analysis
Immune biomarkers profiling in preclinical and clinical samples.
Read more

Cancer immunotherapy Latest News

  • Combination of in vivo efficacy monitoring with intratumoral biopsy to assess new cancer therapies & decipher their MoA

    Combination of intratumoral biopsy with in vivo efficacy monitoring to assess new cancer therapies & decipher their MoA Explicyte is proud to announce the recent development and validation of our new syngeneic subcutaneously-implanted MCA-205 sarcoma tumor mouse model. ...

  • Immunosuppressive tumor microenvironment in OT 4T1 breast tumor model

    While known and validated as non-responsive to conventional immune checkpoint inhibitors, our OT syngeneic mammary tumor model, which represents an aggressive model of human breast carcinoma, is characterized by the presence of at least two types of tumor-infiltrating immunosuppressive cells – myeloid suppressive cells (MSC) and T regulatory cells (Treg). Such cell populations are known, as a result, to suppress effector immune cell responses, thereby promoting tumor immune escape and metastasis....

  • New In vivo syngeneic subcutaneous CT26 colon tumor model Shuttle session

    Because of the success of previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, Explicyte is planning a new shuttle on the CT26 tumor-bearing mouse model, which will take place in October. In this shuttle, our well-characterized syngeneic CT26 colon tumor-bearing mouse model will be used through standardized study protocols, for the evaluation of potential anti-tumor benefits from drug combinations with reference immune checkpoint inhibitors or chemotherapies. ...

Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from cell-based assays - for the phenotypic screening of novel immunotherapeutics and the in vitro determination of the molecular mechanism of action of new anti-cancer immune modulators - to in vivo studies, using syngeneic mouse tumor models treated with antitumor immunotherapies such as immune checkpoint inhibitors (anti CTLA-4  monoclonal antibodies, anti PD1/PDL-1 antibody  therapy and IDO/TDO inhibitors). Furthermore, we offer to explore the in vivo mechanism of action of innovative immunotherapies such as anti-cancer vaccines through the profiling of the anti-tumor immune response by flow cytometry, high-content imaging and RT-qPCR. All our drug development services for cancer immunotherapy are performed in Bordeaux, France. However, we routinely serve clients in the US, EU, UK, Germany and Switzerland.